The use of PE38 for cancer therapy has attracted considerable attention for a long time. However, the extensive use of PE38 is prohibited by its severe side effects. Even though immunotoxin PE38 has been researched for cancer therapy, it has displayed low antitumor activity. The aim of this study is to compare the killing efficacy on Hepatocellular carcinoma (HCC) SMMC-7721 cell of immunoliposome PE38, immunotoxin PE38 and liposome PE38. In this study, the sterically stabilized liposomal PE38 was prepared using soybean phosphatidylcholine, cholesterol, and Cholesterol-PEG-COOH. The humanized anti-hepatoma disulfide-stabilized Fv (hdsFv25) was coupled to sterically stabilized liposomes using the N-hydroxysuccinimide ester method. The immunoliposome PE38 was prepared in our lab using the above-mentioned single-chain antibody. The hdsFv25-immunoliposomes were immunoreactive as determined by ELISA assay. Immunoliposome PE38 can kill SMMC-7721 cells in vitro with higher efficiency than non-targeted liposomes. These results indicate that immunoliposome PE38 may be potential in the treatment of hepatocarcinoma.
ZhangXPBingDQianM. Application of recombinant immunotoxin PE in tumour targeted therapy. Immunol J2004; 20:52–55.
2.
XiYZZhengLYSunYY. Molecular design and construction of L1-6D24-PE40kDEL, a novel recombinant in terleukin6-pseudomonas exotoxin fusion protein, having targeted cytotoxity for leukemias expressing interleukin6 receptors. Hum Immunol2003; 64:247–8.
3.
BangSNanataSOnadaMPincusSHMarcotteTKForsythBM. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res2005; 11:1545–50.
4.
MadhuSSNarayanasamyKMandipS. Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin. J Control Release2001; 76:285–95.
5.
BenbrookDM. An ELISA method for detection of human antibodies to an immunotoxin. Jo Pharmacol Toxicol Meth2002; 47:169–175.
6.
WangHJDaiJXLiBHFanKXPengLZhangDPCaoZGQianWZWangHZhaoJGuoYJ. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A. Protein Expr Purif2008; 58:140–7.
7.
MartinKRainerHaukeL. Design of a modular-immunotoxin connected by polyionic adapter peptides. J Molec Biol2003; 327:445–52.
8.
HeDYangHLinQHuangH. Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells. Int J of Biochem Cell Biol2005; 37:192–205.
9.
Ki-UkKDanielAValleraNKwanHStephenRSpellmanHWalterCWalterA. Immunotoxin therapy for primary malignant brain tumors. Int Congress Series2002; 1247:185–97.
10.
NielsenUBKirpotinDBPickeringEM. Therapeutic efficacy of anti-ErbB2 immnoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta2002; 1591:109–18.
11.
ParkJWHongKKirpotinDBColbernGShalabyMRBaselgaY. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin. Cancer Res2002; 8:1172–81.
12.
MaruyKHolmbergEKennelSJ. Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J Pharm Sci1990; 79:978–84.
13.
OndaMWangQCGuoHF. In Vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res2004; 64:1419–24.
14.
YangTCuiFDChoiMKChoJWChungSJShimCKKimDD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm2007; 338:317–26.
15.
ParkJWKirpotinDBHongKShalabyRShaoYNielsenUBMarksJDPapahadjopoulosDBenzCC. Tumor targeting using anti-her2 immunoliposomes. J Control Release2001; 74:95–113.
16.
YuanQAYuWY. Gene construction and expression in colibacillus of hepatoma specific mouse and humanized single-chain antibody. J Bioeng2000; 16:86–90.
17.
SunZWLiuYF. The initial empirical study of fusing and targeting of single-chain antibody against hepatoma and TNFα. J Cells Molec Immunol2001; 17:69–72.
18.
ZhaoJSunZWLiuYF. Construction expression and function test of the fusion gene of stabilized disulfide bond single-chain antibody against hepatoma and PE38. Cell Mol Immunol2003; 19:585–7.
19.
LuJJeonELeeBSOnyukselHWangZJ. Targeted drug delivery crossing cytoplasmic membranes of intended cells via ligand-grafted sterically stabilized liposomes. J Control Release2006; 110:505–13.
20.
YangTChoiMKCuiFDWelsWBiburgerMMullerT. Preparation and evaluation of paclitaxelloaded PEGylated immunoliposome. J Control Release2007; 120:169–77.
21.
KreitmanRJWilsonWHBergeronKNagataKKomatsuT. Efficacy of the anti-CD22 recombinnant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med2001; 345:241–7.
22.
KreitmanRJMarguliesIStetler-StevensonMWangQC. Cytotoxic activity of disulfide stabilized recombinant immunotoxin RFB4(dsFv) PE38(BL22) toward fresh malignant cells from patients with B cell leukemias. Clin Cancer Res2000; 6:1476–87.
23.
FengBTomizawaKMichiueH. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials2009; 30:1746–55.
24.
ParkJWBenzCCMartinFJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol2004; 31:196–205.
25.
KnechtleSJ. Treatment with immunotoxin. Philos Trans R SOc Lond B Biol Sci2001; 356:681–89.
26.
KhawBJoseDAWilliamCHartnerW. Cytoskeletal-antigen specific immunoliposometargeted in vivo preservation of myocardial viability. J Control Release2007; 120:35–40.
27.
HuHYChengDWLiuYFQiaoMXZhaoXL. Preparation and selectivity to tumor cells in vitro of bee venom polypeptide sterically stabilized immunoliposome. Acta Pharmaceutica Sinea2007; 42:1201–5.
28.
HuHYChengDWLiuYFDengYHYangSJQiaoMXZhaoJZhaoXL. Target ability and therapy efficacy of immunoliposomes using a humanized anti-hepatoma disulfide-stabilized Fv fragment on tumor cells. J Pharm Sci2006; 95:192–9.
29.
HuHYChengDWLiYFZhangXG. Effect of growth inhibition and apoptosis induction of polypepetides in bee venom on human hepatoman cell line SMMC-7721 in vitro and Balb/c nude mice in vivo. J Pharm Pharmaco2006; 58:83–9.
30.
HouXZhangYFXieSS. Target ability of the third generation carried drugs immunoliposomes in vitro and in vivo. Acta Pharmaceutica Sinea2001; 36:539–42.
31.
ZhangYFXieSHHouXP. Preparation and distribution of active carboxyl terminal and long circulation liposomes. Acta Pharmaceutica Sinea2000; 35:854–9.
32.
KepplerAKreitmanRJPastanG. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer2000; 87:86–94.
33.
OndaMNagataSTsutsumiY. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res2001; 61:5070–7.
